First in Human Dose Escalation Study Evaluating the Safety and Immunogenicity of IVT's Shigella-04 Vaccine in Healthy Young Adults

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-10-09

Study Completion Date

2026-08-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Phase 1 trial to evaluate the Safety and Immunogenicity of Inventprise's (IVT) Shigella-04 in Healthy Young Adults

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Invaplex 50 Vaccine Dose-Ranging

NCT00082069

Diarrhea

COMPLETED PHASE1

Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults

NCT00679172

Typhoid

COMPLETED PHASE2

A Study in Healthy Adults to Evaluate the Safety and Immunogenicity of Different Doses of JNJ-63871860

NCT02546960

Healthy

COMPLETED PHASE2

A Safety and Immunogenicity Study of Intranasal Sendai Virus Vectored Respiratory Syncytial Virus (SeVRSV) Vaccine in Healthy Adults

NCT03473002

Antiviral Prophylaxis Respiratory Syncytial Virus Infection

COMPLETED PHASE1

Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects

NCT00498654

Typhoid Fever

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A phase 1 single-site, randomized, double-blind, placebo-controlled, dose-escalation clinical trial to evaluate the safety and immunogenicity of a 2-dose regimen of IM injection of 5 dose formulations of IVT Shigella-04 vaccine with and without adjuvant among 60 healthy individuals aged 18 to 49 years. Approximately 12 eligible participants will be enrolled in the specified 5 sequential dose cohorts and randomized in a 5:1 ratio to receive 2 IM injections of IVT Shigella-04 or placebo (normal saline) at a 28-day interval.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Shigella Diarrhea

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Subjects are randomized in five groups in a 5:1, each receiving 2-doses of IVT Shigella-04 or placebo.

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Subjects and investigators will be blinded to treatment assignment. The vaccine and placebo will be prepared and administered by dedicated unblinded staff not involved in other aspects of the study and will be concealed from the participant at the time of dosing. Unblinding will occur only after database lock or in the event of a medical emergency requiring knowledge of treatment allocation.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Shigella-04 Low Dose without adjuvant (0.5 mL dose)

Subjects will receive a 0.5 mL dose of the Shigella-04 low-dose formulation of each conjugated OPS, and administered via intramuscular injection on Day 1 and 29

Group Type EXPERIMENTAL

IVT Shigella-04

Intervention Type BIOLOGICAL

Preventative vaccine for Shigella protection against 4 unique serotypes

Shigella-04 Low Dose with adjuvant (0.5 mL dose)

Subjects will receive a 0.5 mL dose of the Shigella-04 low-dose formulation of each conjugated OPS, with adjuvant, administered via intramuscular injection on Day 1 and 29

Group Type EXPERIMENTAL

IVT Shigella-04

Intervention Type BIOLOGICAL

Preventative vaccine for Shigella protection against 4 unique serotypes

Shigella-04 Medium Dose without adjuvant (0.5 mL dose)

Subjects will receive a 0.5 mL dose of the Shigella-04 medium-dose formulation of each conjugated OPS, and administered via intramuscular injection on Day 1 and 29

Group Type EXPERIMENTAL

IVT Shigella-04

Intervention Type BIOLOGICAL

Preventative vaccine for Shigella protection against 4 unique serotypes

Shigella-04 Medium Dose with adjuvant (0.5 mL dose)

Subjects will receive a 0.5 mL dose of the Shigella-04 medium-dose formulation of each conjugated OPS, with adjuvant, administered via intramuscular injection on Day 1 and 29

Group Type EXPERIMENTAL

IVT Shigella-04

Intervention Type BIOLOGICAL

Preventative vaccine for Shigella protection against 4 unique serotypes

Shigella-04 High Dose without adjuvant (1.0 mL dose)

Subjects will receive a 1.0 mL dose of the Shigella-04 high-dose formulation of each conjugated OPS, and administered via intramuscular injection on Day 1 and 29

Group Type EXPERIMENTAL

IVT Shigella-04

Intervention Type BIOLOGICAL

Preventative vaccine for Shigella protection against 4 unique serotypes

Placebo - 0.9% Saline

0.9% saline

Group Type PLACEBO_COMPARATOR

Placebo (0.9% saline)

Intervention Type BIOLOGICAL

Subjects dosed with 0.9% saline

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

IVT Shigella-04

Preventative vaccine for Shigella protection against 4 unique serotypes

Intervention Type BIOLOGICAL

Placebo (0.9% saline)

Subjects dosed with 0.9% saline

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Placebo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Participants who meet all the following criteria may be included in the study:

1. Age 18 to 49 years at the time of Dose 1
2. Good general health status, as determined by medical history, physical examination, safety laboratory tests, ECG, vital signs, and clinical judgment
3. BMI ≥ 18.0 kg/m2 and ≤ 32.0 kg/m2
4. Negative alcohol breath test and urine drug screen results at Screening and on Day 1
5. All women: negative serum pregnancy test at Screening and negative urine pregnancy on Day 1
6. Women of childbearing potential (see definition in Section 6.6.1): willingness to use a highly effective form of contraception (see list in Section 6.6.1) through 28 days after the last IP dose
7. Willingness to attend all protocol visits and to have all protocol-required procedures
8. Provision of written informed consent

Exclusion Criteria

Participants who meet any of the following criteria will be excluded from the study:

1. Currently lactating
2. History of shigellosis or participation in a Shigella challenge study
3. History of bloody diarrhea without alternative diagnosis
4. History of inflammatory bowel disease
5. History of anaphylaxis or angioedema
6. History of malignancy, excluding nonmelanoma skin cancer, cervical carcinoma in situ, and malignancies considered cured \> 5 years prior to Day 1
7. History of diabetes mellitus (Individuals with diet-controlled diabetes or history of gestational diabetes are eligible if screening blood glucose is normal and there has been no requirement for antidiabetic medication in the last year.)
8. Known hypersensitivity to any of the ingredients in IVT Shigella-04
9. Inadequate venous access for repeated phlebotomy
10. Any screening laboratory test result outside the normal range and grade ≥ 2 according to the FDA's toxicity grading scale for vaccine trials in healthy adults and adolescents; (Elevated creatine kinase and isolated elevations of bilirubin may be Grade 2 if hepatic transaminases are normal and the Investigator attributes the abnormality to exercise or Gilbert's syndrome. Potential cases of benign ethnic neutropenia should be discussed with the Medical Monitor)
11. Positive serologic test for human HIV-1 or HIV-2 antibody, hepatitis B surface antigen, or hepatitis C antibody
12. Immunodeficiency or chronic administration (\> 14 consecutive days) of immunosuppressant or other immune-modifying drugs (see details in Section 6.6.2), including systemic glucocorticoids, within 6 months before Day 1 (topical, intra-articular, or inhaled glucocorticoids permitted)
13. Previous receipt of a licensed or investigational Shigella vaccine
14. Planned receipt of any other vaccine through Day 57
15. Receipt of blood transfusion or blood product within 6 months before Day 1 or planned receipt through Day 57
16. Receipt of any other IP within 90 days before Day 1 or planned receipt through the end of the study
17. Planned elective hospitalization or surgical procedure through the end of the study
18. Occupational exposure to Shigella (eg, laboratory work)
19. Residence ≥ 6 months in a low-income or lower-middle-income country as defined by the World Bank (https://datatopics.worldbank.org/world-development-indicators/the-world-by-income-and-region.html)
20. Employee of Inventprise, vendors, or research sites associated with the study
21. Any medical, psychiatric, substance use, or social condition that, in the judgment of the Investigator, may pose a risk to the participant or interfere with protocol adherence, assessment of study objectives, or ability to provide informed consent

Temporary Delay Criteria

Administration of IVT Shigella-04/placebo will be delayed for any participant who meets any of the following criteria:

1. Receipt of any vaccine in the past 7 days
2. Febrile illness (eg, oral temperature ≥ 38.0°C), diarrhea, or other acute illness in the past 48 hours
3. Presence of any other sign, symptom, or medication use that could inhibit the proper vaccine administration of IVT Shigella-04/placebo or interpretation of diary data

These criteria are temporary or self-limiting, and IVT Shigella-04/placebo may be administered once the time frame has elapsed/the condition has resolved.

Minimum Eligible Age

18 Years

Maximum Eligible Age

49 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes